Calcium channel blocker drugs market

Calcium Channel Blocker Drugs Market, by Drug Class (Benzothizepine, Dihydropyridine and Phenylalkylamine), by Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others (Blood vessel conditions, Coronary Artery Disease etc.)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Aug 2022
CMI5153
185 Pages
Excel & Pdf
Pharmaceutical

Summary

Calcium channel blocker are available in short acting and long acting form. The response of short acting medication is quick as compare to long acting calcium channel blocker drugs. Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac, others), Felodipine, Isradipine, Nicardipine are the type of calcium channel blocker drug used for the treatment of coronary artery disease, chest pain (angina), irregular heartbeats (arrhythmia) and blood vessel conditions, such as Raynaud's disease.

The global calcium channel blocker drugs market is estimated to be valued at US$ 14,285.3 million in 2022 and expected to exhibit a CAGR of 5.2% over the forecast period (2022-2030).

Figure 1. Global Calcium Channel Blocker Drugs Market Share (%) in Terms of Value, by Region, 2022

Increasing prevalence of hypertension is expected to aid in the growth of the global calcium channel blocker drugs market

According to the World Health Organization 2021, hypertension is a major cause of premature death worldwide.

Moreover, according to the Million Hearts managed by the Centers for Disease Control and Prevention, around 1 out of 2 adults in the U.S. suffer from hypertension. In addition, around 91.7 million adult in the U.S. are recommended prescription medication with lifestyle modifications.

Calcium Channel Blocker Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 14,285.3 Mn
Historical Data for:	2017 to 2021	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.2%	2030 Value Projection:	US$ 21,489.7 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Benzothizepine, Dihydropyridine, Phenylalkylamine By Disease Indications: Hypertension, Chest Pain, Arrhythmias By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:	Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc
Growth Drivers:	Rising incidence of hypertension Launches and approval of calcium channel blocker drug
Restraints & Challenges:	Side effect associated with calcium channel blocker drug

Figure 2. Global Calcium Channel Blocker Drugs Market Share (%), by Drug Class, 2022

Global Calcium Channel Blocker Drugs Market: Restraint

Side effects associated with to calcium channel blockers drug such as, headache, rapid heart rate, edema and constipation are expected to inhibit the market growth during the forecast period for the companies and products.

Key Players

Major players operating in the global calcium channel blocker drugs market include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,

Table of Content

Table of Contents

*Browse 29 market data tables and 32 figures on "Global Calcium Channel Blocker Drugs Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global calcium channel blocker drugs market during the forecast period (2022-2030)?

The global calcium channel blocker drugs Market size is estimated to be valued at US$ 14,285.3 million in 2022 and expected to exhibit a CAGR of 5.2% between 2022 and 2030.

What are the major factors driving the market growth?

Rising incidence of hypertension and increasing launches and approval of drug is expected to drive the market growth over the forecast period.

Which is the leading drug class segment in the market?

Dihydropyridines drug class segment is expected to hold the major market share in the market

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering the growth of the market?

Major factors hampering the calcium channel blocker drugs market growth include side effect associated with calcium channel blocker drug.

Which are the major players operating in the market?

Major players operating in the market include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,